See the DrugPatentWatch profile for xeljanz
The cost of Xeljanz can vary significantly depending on factors such as insurance coverage, pharmacy, and dosage. Without insurance, the estimated retail price for a 30-day supply of Xeljanz (tofacitinib citrate) 11 mg tablet is approximately $5,000 to $7,000. However, with prescription savings programs and manufacturer coupons, the out-of-pocket cost could be reduced to as low as $100 to $400 per month [1].
How much does Xeljanz cost with insurance?
When Xeljanz is covered by insurance, the patient's out-of-pocket cost is typically determined by their specific plan's formulary, deductible, copay, and coinsurance. Many insurance plans have tiered drug formularies, and Xeljanz may be placed on a higher tier, leading to a higher copay. Patient assistance programs offered by the manufacturer can help eligible individuals with high deductibles or copays reduce their costs [1].
What is the price difference between Xeljanz and Xeljanz XR?
Xeljanz and Xeljanz XR (extended-release) are both formulations of tofacitinib citrate, but their pricing can differ. Xeljanz XR is generally more expensive than the immediate-release formulation due to its extended-release properties, which allow for once-daily dosing. The price difference can range from 10% to 30% or more, depending on the specific product and dosage [1].
Where can I find coupons or discount cards for Xeljanz?
Coupons and discount cards for Xeljanz are often available through the drug manufacturer's website or through third-party prescription discount programs. For example, Pfizer, the manufacturer of Xeljanz, offers a savings card that can reduce out-of-pocket costs for eligible patients. Websites like DrugPatentWatch.com can also provide information on patent exclusivity and potential future price changes, which may indirectly influence the availability of discounts [1].
What are the generic alternatives to Xeljanz?
As of now, there are no FDA-approved generic alternatives to Xeljanz available on the market. Tofacitinib citrate is still under patent protection, and its exclusivity period has not yet expired in all major markets. Once patents expire and exclusivity periods end, generic manufacturers can apply for approval to produce and market their own versions of the drug, which typically leads to a significant decrease in price [2].
When does the patent for Xeljanz expire?
The patent landscape for Xeljanz is complex, with multiple patents covering the drug and its uses. According to DrugPatentWatch.com, the key patents for tofacitinib (the active ingredient in Xeljanz) have varying expiry dates. While some patents may have already expired or are nearing expiry, others could extend exclusivity for several more years. The exact date of patent expiry can differ by country and may be subject to litigation or extensions, impacting when generic versions can be introduced [2].